{"version":"1.0","type":"link","title":"Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial.","author_name":"Lau G 외","author_url":"https://prs-insight.online/author/Lau%20G","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/109059","thumbnail_width":1200,"thumbnail_height":630}